Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KN5502 is a chimeric antigen receptor (CAR)-engineered natural killer (NK) cell therapy being developed by Rui Therapeutics (Shenzhen Enrui Kainuo Biotechnology Co., Ltd.). The therapy is designed to leverage the innate cytotoxic potential of NK cells, enhanced by the specificity of a chimeric antigen receptor to target and eliminate specific cells. As of early 2024, KN5502 is in the early preclinical research and development stage, with its specific molecular target and therapeutic indication currently undisclosed by the developer.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on KN5502.